Verastem, Inc.
(NASDAQ : VSTM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.62%179.461.2%$611.65m
CELGCelgene Corporation
1.34%77.641.2%$572.88m
GILDGilead Sciences, Inc.
0.60%68.230.9%$554.20m
BIIBBiogen Inc.
1.48%283.821.2%$528.32m
REGNRegeneron Pharmaceuticals, Inc.
0.19%295.252.6%$309.14m
ILMNIllumina, Inc.
0.36%271.773.5%$236.20m
VRTXVertex Pharmaceuticals Incorporated
0.18%156.561.9%$230.83m
ALXNAlexion Pharmaceuticals, Inc.
-0.65%118.242.0%$223.47m
AAgilent Technologies, Inc.
-0.54%64.491.5%$209.62m
NKTRNektar Therapeutics
0.28%82.186.0%$198.86m
INCYIncyte Corporation
0.35%66.792.5%$177.25m
SRPTSarepta Therapeutics, Inc.
-0.70%88.6016.6%$124.14m
BMRNBioMarin Pharmaceutical Inc.
1.96%89.334.4%$119.64m
EXASExact Sciences Corporation
-3.15%51.3225.5%$112.41m
BLUEBluebird Bio, Inc.
1.80%189.0015.7%$96.43m

Company Profile

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.